Clinical Trials Logo

Cardio-Renal Syndrome clinical trials

View clinical trials related to Cardio-Renal Syndrome.

Filter by:

NCT ID: NCT06174623 Not yet recruiting - Heart Failure Clinical Trials

Feasibility Study to Support Cardiorenal Function in Acute Decompensated Heart Failure With Diuretic Resistance

Start date: August 2024
Phase: N/A
Study type: Interventional

Evaluation of the safety and efficacy of the ModulHeart System in patients hospitalized with acute decompensated heart failure (ADHF) and diuretic resistance

NCT ID: NCT06111768 Recruiting - Clinical trials for Cardiorenal Syndrome

Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

SGLT2i in CRS
Start date: May 30, 2024
Phase: Phase 2
Study type: Interventional

The long-term objective of this study is to test whether the addition of SGLT2 inhibitors to usual care during acute heart failure management in patients who develop kidney injury shortens the time to achieving symptomatic improvement and kidney function recovery. The study aims to assess feasibility and acceptability of such a randomized clinical trial.

NCT ID: NCT06065163 Recruiting - Clinical trials for Cardiorenal Syndrome Type 1

Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome

NEEDED
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

A double-blind, randomized, controlled trial was conducted with the main objective of evaluating if patients with clinical assessment and VExUS reach decongestion faster within a maximum period of 7 days during the hospital stay. Likewise, the study will describe those patients who experience a decrease in serum creatinine (CrS), NT-proBNP at discharge, greater diuretic adjustment, rate of intrahospital readmission, and 30-day mortality.

NCT ID: NCT06030843 Not yet recruiting - Clinical trials for Empagliflozin in Cardiorenal Syndrome Type 1

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

TREAT-CRS
Start date: March 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.

NCT ID: NCT05927285 Completed - Acute Kidney Injury Clinical Trials

Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1

Start date: March 20, 2022
Phase: N/A
Study type: Interventional

During cardiorenal syndrome type 1 (CRS1) vascular congestion is the major contributor to worsening renal function, but promoting decongestion with routine clinical evaluation is ineffective in some patients. The venous evaluation by ultrasound (VExUS) may optimize its management when evaluating for improvement in kidney function and other metrics related to decongestion.

NCT ID: NCT05677100 Recruiting - Heart Failure Clinical Trials

Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

DRAIN-HF
Start date: August 23, 2023
Phase: N/A
Study type: Interventional

Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and are resistant to diuretic therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.

NCT ID: NCT05428631 Recruiting - Heart Failure Clinical Trials

Tolerability and Safety of CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients With Cardio Renal Syndrome With Severe Renal Impairment

CARDIOMEMS
Start date: August 26, 2022
Phase: N/A
Study type: Interventional

Renal failure is present in 40% of heart failure patients, and is one of the main comorbidities of heart failure. Follow-up with pulmonary artery pressure (PAP) monitoring has shown a reduction in mortality and frequency of hospitalization in patients with heart failure alone in the CHAMPION trial. Patients with New York Heart Association class III heart failure and a hospitalization in the previous 12 months were included in that study. They benefited from the "CardioMEMS™ HF" device with a sensor implanted in the pulmonary artery to measure PAP. According to that study, the information led to more precise and early adaptation of therapy by avoiding the onset of heart failure symptoms and reducing the number of hospitalizations. However, in that study, patients with impaired renal function (Glomerular Filtration Rate<25 mL/min/1.73m2) were excluded, limiting the indication for treatment in those patients, and the evolution of renal function during the study was not reported. Patients with heart failure AND advanced renal failure are defined as having a cardio-renal syndrome, with strong interaction between these 2 organs. In the event of predominant right heart failure, they may require treatment by renal replacement or dialysis. There seems to be a link between high venous pressure, renal repercussions and the need for dialysis. Additional follow-up data in this clinical situation are needed to confirm this link and to suggest the interest of continuous PAP monitoring to improve the management of these patients with cardio-renal syndrome with severe renal impairment defined by a Glomerular Filtration Rate< 30 ml/min/1.73m2 (KDIGO Cardio-renal 2019). This pilot study aims to evaluate how tolerable the "CARDIOMEMS™ HF" device in patients with cardio-renal syndrome and obtain the first information on the relationship between cardiac hemodynamics and renal function in this population.

NCT ID: NCT05397392 Recruiting - Heart Failure Clinical Trials

Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome

ODT-CRS
Start date: January 2016
Phase:
Study type: Observational

To estimate the characteristics, pathogenesis, risk factors and intervention measures for different stages of heart and kidney diseases, and to optimize the curative effects of different treatment schemes

NCT ID: NCT05368766 Not yet recruiting - Clinical trials for Cardio-Renal Syndrome

Predictive Value of Venous Excess Ultrasound Score in Management of Cardiorenal Patients

Start date: June 1, 2022
Phase:
Study type: Observational [Patient Registry]

To assess predictive value of venous excess ultrasound score in cardiorenal patient management

NCT ID: NCT05079724 Not yet recruiting - Heart Diseases Clinical Trials

Acute Kidney Injury After Cardiac Surgery

Start date: November 1, 2021
Phase:
Study type: Observational

The study aims to identify the Following: - 1. incidence and mortality of cardiac Surgery associated -AKI based on the new consensus diagnostic systems of KDIGO (Kidney Disease Improving Global Outcomes). 2. use of biomarkers for the early detection of clinical and subclinical cardiac Surgery associated-AKI. 3. risk factors and prediction models of cardiac Surgery associated-AKI. 4. optimal cardiac surgical procedures including conventional versus minimally invasive approaches, on-pump versus off-pump, and optimal management of cardiac surgical support including duration of CPB, perfusion pressure, hemodilution, and hypothermia during CPB. 5. controversial pharmacologic therapies for the prevention and treatment of cardiac Surgery associated-AKI including statins, sodium bicarbonate, and N-acetylcysteine (NAC).